Dermatomycoses: Clinical Trials

24 trials for Dermatomycoses, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

24 completed. 24 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 424Completed 24

Follow Dermatomycoses: new trials by email Literature Review of Dermatomycoses trials Research Report on Dermatomycoses

Trials (filtered) newest first · largest first

All 24 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Oral Fluconazole vs Oral Terbinafine for Tinea Capitis in Children Aged 2-10 Years
Fluconazole., Terbinafine., Ketoconazole 2% shampoo - Tinea Capitis
Phase 4CompletedDr. Amara Safdar642025-12-012026-11-10
8% Sulphur-Aloe Vera Soap as an Adjuvant Treatment for Pityriasis Versicolor
8% sulphur and A. vera soap - Pityriasis Versicolor
Phase 4CompletedUniversitas Padjadjaran422023-08-252024-03-26
Topical Amphotericin B in 30% Dimethylsulphoxide in Treating of Non-dermatophytes Onychomycosis
amphotericin B in 30% DMSO, 30% DMSO - Fungal Infection, Onychomycosis
Phase 4CompletedMahidol University192019-01-152021-09-28
The Comparative Assessment of Mycological Efficacy, Safety, Recurrence, and Cost-effectiveness of Selenium Sulfide 1.8% Shampoo Versus Ketoconazole 2% Shampoo in Pityriasis Versicolor: a Double-blind Randomized Controlled Trial
shampoo with different composition - Pityriasis Versicolor
Phase 4CompletedUniversitas Indonesia1002018-09-012019-07-05
Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Jublia® in Mild to Moderate Toenail Onychomycosis
Jublia® - Mild to Moderate Onychomycosis Due to Dermatophyte
Phase 4CompletedDong-A ST Co., Ltd.972017-11-102021-04-27
Safety and Pharmacokinetics of Efinaconazole Topical Solution in Subjects With Mild to Severe Onychomycosis
Efinaconazole - Onychomycosis
Phase 4CompletedBausch Health Americas, Inc.622016-08-042021-11-01
Comparison Between Long-pulsed Nd:YAG, Amorolfine and Combination Treatment in Treating Non-dermatophyte Onychomycosis
1,064nm Long-pulsed Nd:YAG, Amorolfine - Non-dermatophyte Onychomycosis
Phase 4CompletedMahidol University602016-08-012021-09-28
Safety and Efficacy of Product 33525 (Luliconazole Cream 1%) in Pediatric Participants With Tinea Corporis
Luliconazole Cream 1%, Vehicle Cream - Tinea Corporis
Phase 4CompletedBausch Health Americas, Inc.752016-02-082019-11-27
Treatment of Onychomycosis With Loceryl (Amorolfine) Nail Lacquer 5% Versus a Two-course Treatment With Urea 40% Ointment and Bifonazole Cream 1%
Loceryl Nail Lacquer, Urea Ointment, Bifonazole Cream - Foot Dermatoses
Phase 4CompletedGalderma R&D222016-01-012021-02-17
Maximal Use of Luliconazole Cream 1% in Pediatric Participants With Moderate to Severe Tinea Pedis or Tinea Cruris
Luliconazole Cream 1% - Tinea Pedis, Tinea Cruris
Phase 4CompletedBausch Health Americas, Inc.302015-12-022019-11-27
An Evaluation of the Safety and Pharmacokinetics of Tavaborole Topical Solution for the Treatment of Fungal Disease of the Toenail in Children and Adolescents
Tavaborole 5% Topical Solution - Onychomycosis, Tinea Unguium
Phase 4CompletedPfizer552015-10-222018-04-17
Study Evaluating the Effect of Jublia on Dermatophytomas
Jublia (Efinaconazole 10% Topical Solution) - Onychomycosis, Dermatophytosis
Phase 4CompletedUniversity of Alabama at Birmingham192015-09-012019-12-10
Treatment of Onychomycosis With Loceryl (Amorolfine) Nail Lacquer 5% Versus Ciclopirox Nail Lacquer
Loceryl NL, Ciclopirox NL - Foot Dermatoses
Phase 4CompletedGalderma R&D202015-09-012021-03-22
A Pilot Study - Safety and Efficacy of Nailprotex® for Onychomycosis Treatment
Nailprotex - Onychomycosis, Chronic Paronychia
Phase 4CompletedMahidol University192015-07-012016-06-17
Study Evaluating the Drug Interaction Potential of Luliconazole Cream 1% in Participants With Tinea Pedis and Tinea Cruris
Omeprazole 40 mg, Luliconazole Cream 1% - Tinea Pedis, Tinea Cruris
Phase 4CompletedBausch & Lomb Incorporated202015-02-032019-11-27
Pediatric Subjects With Tinea Corporis
Naftin Cream, Placebo Cream - Tinea Corporis
Phase 4CompletedMerz North America, Inc.2302014-08-012016-10-28
Antifungal Activity of Loceryl Nail Lacquer in Combination With a Cosmetic Varnish
Loceryl NL + Cosmetic varnish, Loceryl NL 12 weeks, Loceryl NL 15 months - Foot Dermatoses
Phase 4CompletedGalderma R&D502014-02-012023-01-19
An Open Label Pharmacokinetic Study of Naftin for Tinea Corporis
Naftin® Cream, 2% (younger pediatric cohort), Naftin® Cream, 2% (older pediatric cohort) - Tinea Corporis
Phase 4CompletedMerz North America, Inc.272014-01-012016-10-28
Resin vs. Amorolfine vs. Terbinafine Treatment in Onychomycosis
Resin Lacquer, Amorolfine, Terbinafine - Onychomycosis
Phase 4CompletedHelsinki University Central Hospital1292013-10-012015-11-30
Pharmacokinetic Study of Pediatric Subjects With Tinea Cruris and Tinea Pedis
NAFT500 (pediatric), NAFT600 (pediatric), NAFT500 (adult) - Tinea Pedis, Tinea Cruris
Phase 4CompletedMerz North America, Inc.562012-10-012016-07-14

Showing 20 of 24. Sign in to see all of them.

Narrower conditions

Onychomycosis (13)  ·  Tinea (5)  ·  Foot Dermatoses (3)  ·  Tinea Cruris (3)  ·  Tinea Pedis (3)  ·  Tinea Versicolor (3)  ·  Mycoses (2)  ·  Aspergillosis (1)  ·  Mycetoma (1)  ·  Tinea Capitis (1)

Broader conditions

Bacterial Infections and Mycoses (24)  ·  Infections (24)  ·  Skin Diseases (24)  ·  Skin Diseases, Infectious (24)  ·  Skin and Connective Tissue Diseases (24)  ·  Mycoses (22)  ·  Tinea (15)  ·  Nail Diseases (13)  ·  Foot Diseases (6)  ·  Dermatitis (3)  ·  Foot Dermatoses (3)  ·  Intertrigo (3)  ·  Pathological Conditions, Signs and Symptoms (3)  ·  Pruritus (3)

Interventions

efinaconazole (3)  ·  Itraconazole (2)  ·  Ketoconazole (2)  ·  Solutions (2)  ·  Terbinafine (2)  ·  amorolfine (2)  ·  Amphotericin B (1)  ·  Ciclopirox (1)  ·  Dimethyl Sulfoxide (1)  ·  Fluconazole (1)  ·  Omeprazole (1)  ·  Sulfur (1)  ·  Therapeutics (1)  ·  Urea (1)  ·  bifonazole (1)

Sponsors

Bausch Health Americas, Inc. (3)  ·  Galderma R&D (3)  ·  Mahidol University (3)  ·  Merz North America, Inc. (3)  ·  Bausch & Lomb Incorporated (1)  ·  Boni Elewski, MD (1)  ·  Dong-A ST Co., Ltd. (1)  ·  Dr. Amara Safdar (1)  ·  Helsinki University Central Hospital (1)  ·  Janssen Korea, Ltd., Korea (1)  ·  Pfizer (1)  ·  Post Graduate Institute of Medical Education and Research, Chandigarh (1)  ·  Rady Children's Hospital, San Diego (1)  ·  Universitas Indonesia (1)  ·  Universitas Padjadjaran (1)

Countries

United States (9)  ·  Dominican Republic (6)  ·  Honduras (5)  ·  Thailand (3)  ·  Iceland (2)  ·  Indonesia (2)  ·  Finland (1)  ·  Germany (1)  ·  India (1)  ·  Pakistan (1)  ·  Panama (1)  ·  Puerto Rico (1)  ·  South Korea (1)

Top investigators

Anya Loncaric (3)  ·  Alan Fleischer, MD (2)  ·  Boni E Elewski, MD (2)  ·  Alan B. Fleischer, MD (1)  ·  Binu Alexander, MD (1)  ·  Charussri Leeyaphan, MD (1)  ·  Janne J. Jokinen, MD, PhD (1)  ·  Risa Miliawati Nurul Hidayah, MD, Ph.D (1)  ·  Sheila F Friedlander, MD (1)  ·  Sumanas Bunyaratavej, MD (1)

Results publications

PMID 10233295, PMID 10642676, PMID 14723731, PMID 20347657, PMID 21820203, PMID 22236569, PMID 22976905, PMID 23278851, PMID 23416171, PMID 23496375, PMID 24079583, PMID 25013957, PMID 25639524, PMID 26471716, PMID 27799043, PMID 27815659, PMID 30811142

NIH funding

2015 (1)